Browsing Tag
NSE
148 posts
HG Infra Engineering (HGINFRA) wins Rs 519cr Mirzapur thermal power railway contract as stock attempts recovery from 57% decline
HG Infra Engineering (HGINFRA) wins Rs 519.33 crore railway civil works order at Adani Power's Mirzapur thermal plant. Analysis of what it means for investors. Read more.
NTPC just hit record capacity additions, signed a nuclear deal with France and still trades at a discount. Worth watching?
NTPC (NSE: NTPC) hit record FY26 capacity additions and signed an EDF nuclear MoU. With ₹380 CMP and analyst targets to ₹440, here is what retail investors need to know.
Ashok Leyland share price outlook: what next for NSE: ASHOKLEY after the rebound?
Ashok Leyland (NSE: ASHOKLEY) is back in focus after a sharp rebound. Read what comes next, the key catalyst path, and the risks investors should track.
Tata Power (NSE: TATAPOWER): Can the Mundra restart and renewables surge unlock the next leg higher?
Tata Power's Mundra plant restarted April 1 after a nine-month shutdown. With new PPAs, a 23 GW renewable target, and Q4 results due April 26, here's what investors need to know.
Adani Power (NSE: ADANIPOWER): What’s driving the Q4 FY26 earnings moment and the Rs 2 lakh crore expansion bet
Adani Power (NSE: ADANIPOWER) faces Q4 FY26 results on April 28. Here's what the MSEDCL contract, 41.87 GW expansion, and profit decline mean for retail investors.
Wipro (WIT) secures eight-year, $1bn Olam contract and pays $375m for agribusiness IT unit Mindsprint
Wipro secures an $1bn, eight-year Olam Group transformation deal and acquires Mindsprint for $375m. What it means for WIT stock, competitors, and agribusiness IT. Read more.
Cipla Limited (NSE: CIPLA) secures FDA approval for generic nintedanib capsules, entering a $3.8bn U.S. pulmonary fibrosis market
Cipla wins FDA approval for generic nintedanib capsules for IPF, targeting Boehringer Ingelheim's $3.76B Ofev market. Here's what the launch means for investors. Read more.
Granules India (NSE: GRANULES) exits FDA audit with four observations as regulatory scrutiny intensifies
Granules India's Chantilly facility exits a routine US FDA cGMP audit with four procedural Form 483 observations and no data integrity findings. Read what it means for the GRANULES growth outlook.
K.P. Energy (KPEL) signs IPL deal with Delhi Capitals as stock trades 50% below 52-week high
KP Group's three listed companies join Delhi Capitals as IPL associate sponsors for 2026-2028. What does the strategy mean for KPEL and KPIGREEN? Read more.
Eternal (NSE: ETERNAL): Can Blinkit carry the whole company into profit?
Eternal (NSE: ETERNAL) is trading 37% off its October peak. Blinkit just hit EBITDA breakeven. Here is what retail investors need to watch before Q4 FY26 results.